A new cancer drug under development could begin phase 1 testing in humans next year after it obtained good results in treating eight types of cancers in animal tests, the National Health Research Institutes (NHRI) announced yesterday.
Hsieh Hsing-pang (謝興邦), a researcher at the NHRI’s Institute of Biotechnology and Pharmaceutical Research (IBPR), said at a media briefing that 40 late-stage cancer patients who have not been helped by any available treatment, but are still in decent physical condition, are to be recruited for phase 1 clinical trials next year.
The new drug, known as DBPR144, is a small molecule known as a multi-target kinase inhibitor, Hsieh said.
Photo: CNA
A kinase is an enzyme that controls important cell functions, and it can be active in the growth of some types of cancer cells.
The eight types of cancers against which it showed success through in vivo studies in animals were pancreatic, oral, gastric, liver, bladder, prostate and colorectal cancer, as well as acute myeloid leukemia, Hsieh said.
“Because it is particularly effective in gastroenterology-related cancers, we are likely to first target patients with pancreatic, liver, bladder and gastric cancer in the initial clinical trial,” he said.
Multi-target drugs, which take aim at several targets rather than more common medications that only target a single biological substance, more effectively inhibit cancer cell proliferation and overcome drug resistance, he said.
During the phase 1 trial, the volunteers are to be given DBPR114 once a week to determine safe dosages of the drug, Hsieh said.
Chen Chiu-heng (陳丘泓), general manager of Launxp Biomedical Co, which will be responsible for manufacturing the drug, said cancer patients from Taiwan and Australia are to be recruited to take part in the initial trial, which is expected to take two years.
Phase 2 and phase 3 trials, which should each take two to three years, will focus on cancers that responded promisingly to the drug in phase 1.
At least six years will be needed to complete human trials, Chen said.
“This novel, multi-targeted agent is our new hope for treating cancer patients,” IBPR Director Chang Jang-yang (張俊彥) said.
Cancer has been the top cause of death in Taiwan for 41 years, he said, and the five-year survival rates among patients with major types of cancer remained low, especially the 5 percent rate for people with pancreatic cancer.
RESOLUTIONS DEBATE: Taiwan’s allies said that UN and WHA resolutions cited by China and other nations ‘do not determine Taiwan’s participation in WHO activities’ A proposal to invite Taiwan to this year’s World Health Assembly (WHA) was rejected on Monday, resulting in Taipei’s absence from the annual meeting for a ninth consecutive year, although partners spoke up for Taiwan’s participation at the first day of the meeting. The first agenda item after the opening was a “two-on-two debate” on a proposal to invite Taiwan to participate at the WHA as an observer. Similar to previous years, two countries made statements in favor of the proposal, while two others expressed their opposition. Philippine Secretary of Health Teodoro Herbosa, president of the 78th WHA, accepted the WHA General Committee’s
Palauan President Surangel Whipps Jr arrived in Taiwan last night to kick off his first visit to the country since beginning his second term earlier this year. After arriving at Taoyuan International Airport at around 6:30 pm, Whipps and his delegation were welcomed by Minister of Foreign Affairs Lin Chia-lung (林佳龍). Speaking to gathered media, the Palauan leader said he was excited and honored to be back in Taiwan on his first state visit to Taiwan since he was sworn in this January. Among those traveling with Whipps is Minister of State Gustav N. Aitaro, Public Infrastructure
Premier Cho Jung-tai (卓榮泰) on Friday laid out the Cabinet’s updated policy agenda and recapped the government’s achievements ahead of the one-year anniversary of President William Lai’s (賴清德) inauguration. Cho said the government had made progress across a range of areas, including rebuilding Hualien, cracking down on fraud, improving pedestrian safety and promoting economic growth. “I hope the public will not have the impression that the Cabinet only asked the legislature to reconsider a bunch of legal amendments,” Cho said, calling the moves “necessary” to protect constitutional governance and the public’s interest. The Cabinet would work toward achieving its “1+7” plan, he said. The
Nvidia founder and CEO Jensen Huang (黃仁勳) hosted a dinner in Taipei last night with key Taiwanese suppliers to celebrate the successful mass production of the company’s new Blackwell AI systems. Speaking to the media earlier yesterday, Huang thanked Nvidia’s Taiwanese partners for their contributions to the company’s ecosystem, while also sharing his plans to meet with Taiwan Semiconductor Manufacturing Co (TSMC) founder Morris Chang (張忠謀). In response to rumors that Nvidia will launch a downgraded Hopper H20 chip for China in July, Huang dismissed the reports, saying, “That is not true.” He clarified that there
RSS